3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Lymphoma
42
Precursor Cell Lymphoblastic Leukemia-Lymphoma
32
Lymphoma, Large B-Cell, Diffuse
29
Prostatic Neoplasms
28
Lymphoma, Follicular
15
Leukemia
15
Lymphoma, Non-Hodgkin
13
Hodgkin Disease
11
Burkitt Lymphoma
10
Leukemia, Biphenotypic, Acute
8
Recurrence
6
Neoplasms
6
Neoplasm Metastasis
6
Lymphoma, Large-Cell, Anaplastic
6
Lymphoma, B-Cell
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Ovarian Neoplasms
4
Multiple Myeloma
4
Immunoblastic Lymphadenopathy
4
Hemangioma
4
Dendritic Cell Sarcoma, Interdigitating
4
Lymphoma, T-Cell, Peripheral
3
Lymphoma, T-Cell
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, B-Cell, Marginal Zone
3
Breast Neoplasms
3
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Neurotoxicity Syndromes
2
Neoplasm, Residual
2
Interventions
ravulizumab
1
Saline Solution
1
Prednisone
1
Prednisolone
1
Hydrocortisone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Adrenal Insufficiency
×
Prednisolone
×
Clear all
NCT07221838
2026-04-09
OCTAGON
Alexion Pharmaceuticals, Inc.
Phase 4
Recruiting
75 enrolled